Skip to main navigation
Skip to search
Skip to main content
Fox Chase Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at Fox Chase Cancer Center
Home
Profiles
Research Units
Research Resources
Research Outputs
Prizes
Activities
Press/Media
Role of new chemotherapy agents in soft tissue sarcoma
Margaret Von Mehren
Cancer Epigenetics Institute
Cancer Signaling and Microenvironment (CSM)
Hematology Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Role of new chemotherapy agents in soft tissue sarcoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Chemotherapeutic Agent
100%
Drug
100%
Soft Tissue Sarcoma
100%
Gastrointestinal Stromal Tumor
100%
Imatinib
100%
Sarcoma
100%
Chemotherapy Agent
100%
Comprehension
50%
Combination Therapy
50%
Gemcitabine
50%
Docetaxel
50%
Cell Cycle
50%
Protein Serine Threonine Kinase
50%
Growth Factor Receptor
50%
DNA
50%
Doxorubicin
50%
Cell Growth
50%
Trabectedin
50%
Pharmacology, Toxicology and Pharmaceutical Science
Drug
100%
Gastrointestinal Stromal Tumor
100%
Imatinib
100%
Soft Tissue Sarcoma
100%
Sarcoma
100%
Gemcitabine
50%
Docetaxel
50%
Doxorubicin
50%
Cell Cycle
50%
DNA
50%
Protein Serine Threonine Kinase
50%
Trabectedin
50%
Growth Factor Receptor
50%
Biochemistry, Genetics and Molecular Biology
Imatinib
100%
Comprehension
50%
Transcription
50%
Cell Cycle
50%
Kinase
50%
Threonine
50%
Serine
50%
DNA
50%
Cell Growth
50%
Mammalian Target of Rapamycin
50%
Doxorubicin
50%
Gemcitabine
50%
Growth Factor Receptor Inhibitor
50%